Diabetes Research on Patient Stratification

Conditions

Type2 Diabetes

Keywords

Gene-environment interaction, Genome, Glycaemic control, Lifestyle, Microbiome, Prediabetes, Proteome, Type 2 diabetes

Brief summary

The overarching goal of the IMI DIRECT (Innovative Medicines Initiative Diabetes Research on Patient Stratification) Consortium is the identification of biomarkers that aid therapeutic targeting in prediabetes (Study 1) or early onset type 2 diabetes (Study 2).

Detailed description

There are two multicentre prospective cohort studies within the glycaemic deterioration work package of IMI DIRECT (WP2). These two cohorts are designed to address the area of glycaemic deterioration by amassing data and biomaterials that will be used to discover novel biomarkers for glycaemic deterioration in people at high risk of developing type 2 diabetes (Study 1) and in those who have recently been diagnosed with the disease (Study 2).

Lyu L, Fan Y, Vogt JK, Clos-Garcia M, Bonnefond A, Pedersen HK, Dutta A, Koivula R, Sharma S, Allin KH, Brorsson C, Cederberg H, Chabanova E, De Masi F, Dermitzakis E, Elders PJ, Blom MT, Hollander M, Eriksen R, Forgie I, Frost G, Giordano GN, Grallert H, Haid M, Hansen TH, Jablonka B, Kokkola T, Mahajan A, Mari A, McDonald TJ, Musholt PB, Pavo I, Prehn C, Ridderstråle M, Ruetten H, Hart LM', Schwenk JM, Stankevic E, Thomsen HS, Vangipurapu J, Vestergaard H, Viñuela A, Walker M, Hansen T, Linneberg A, Nielsen HB, Brunak S, McCarthy MI, Froguel P, Adamski J, Franks PW, Laakso M, Beulens JWJ, Pearson E, Pedersen O.

2025-07-151 citations

10.1186/s13073-025-01508-7

Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts

Naeimeh Atabaki‐Pasdar, Mattias Ohlsson, Ana Viñuela, Francesca Frau, Hugo Pomares‐Millan et al. (63 authors)

PLoS Medicine2020-06-1988 citations

10.1371/journal.pmed.1003149

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 74 Years

Healthy volunteers

No

Inclusion criteria

Study 1 Inclusion criteria * No treatment with insulin-sensitising, glucose-lowering or other antidiabetic drugs * Fasting capillary blood glucose \<10 mmol/l at baseline * White European (self-report of parental ethnicity) * Age ≥35 and \<75 years

Exclusion criteria

* Diagnosed diabetes of any type, HbA1c ≥6.5% (48 mmol/mol) or fasting plasma glucose ≥7.0 mmol/l or 2 h plasma glucose \>11.0 mmol/l previously * For women, pregnancy, lactation or plans to conceive within the study period * Use of a pacemaker * Any other significant medical reason for exclusion as determined by the investigator Study 2 Inclusion Criteria: * Patients diagnosed with type 2 diabetes not less than 6 months and not more than 24 months before baseline examination * Management by lifestyle with or without metformin therapy * All HbA1c \<7.6% (\<60 mmol/mol) within previous 3 months * White European * Age ≥35 and \<75 * Estimated GFR \>50 ml/min'

Design outcomes

Primary

Measure	Time frame	Description
Glycemic deterioration	Up to 10 years follow-up	Change in glucose (or HbA1c) over time and/or progression to anti diabetic medications/insulin

Outcome results